

Inflammatory Bowel Diseases (IBD) Therapeutic and Drug Pipeline Review H2

Inflammatory Bowel Diseases (IBD) - Analysis by stage of development, drug target, mechanism of action, route of administration and molecule type

PUNE, INDIA, August 30, 2017 /EINPresswire.com/ -- Pune, India, 30th August 2017: WiseGuyReports announced addition of new report, titled "Irritable Bowel Syndrome - Pipeline Review, H2 2016". □

Summary

[Inflammatory Bowel Diseases](#) (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/752817-irritable-bowel-syndrome-pipeline-review-h2-2016> □

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively. Irritable Bowel Syndrome.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Irritable Bowel Syndrome Overview 10

Therapeutics Development 11

Pipeline Products for Irritable Bowel Syndrome - Overview 11

Irritable Bowel Syndrome - Therapeutics under Development by Companies 12

Irritable Bowel Syndrome - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Irritable Bowel Syndrome - Products under Development by Companies 17

Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 19

4D Pharma Plc 19

A. Menarini Industrie Farmaceutiche Riunite Srl 20

Alfa Wassermann S.p.A 21

Ardelyx, Inc. 22

Astellas Pharma Inc. 23

CJ HealthCare Corp. 24

Dong-A Socio Holdings Co. Ltd. 25

Enterome Bioscience SA 26

GlaxoSmithKline Plc 27

...Continued□

[pipeline-review-h2-2016](#) □

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

Wise Guy Consultants Pvt. Ltd.

+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.